Search

Cutting Edge Gastroenterology Research

All of us here at DHAT take great pride in providing the most up to date medical and surgical gastroenterology care based on the principles of best practices and evidence based delivery. In 2016, we were pleased to announce the birth of the DHAT Research Institute (DRI). Through this new Clinical Research Institution, located in Richardson, Texas, we are now offering patients access to future treatments in gastroenterology care.

In order for new treatments and therapies to receive FDA approval, they must pass through four different phases. Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. DHAT Research Institute will be participating in all four Phases, 1 through 4, but its primary focus will include clinical trials that are in Phase 2 and Phase 3 clinical trials.

DHAT Research Institute will be participating in multiple clinical trials giving patients access to new treatments before they are FDA approved and available to the general public. We are currently looking to offer opportunities for patients with Crohn’s Disease, Ulcerative Colitis, Gastroparesis, Fatty Liver Disease, Hepatitis B and C, gastrointestinal infections including Clostridium Difficile, H. Pylori, and Eosinophilic Esophagitis. DHAT Research Institute is excited to bring the future of gastroenterology medicine to adults and pediatrics in the Dallas-Fort Worth area. For more information regarding clinical trials, please reach out to one of our Clinical Research Coordinators at (972) 265-8201 or email us at research@dhat.com.

Participate in a Clinical Trial

Current Clinical Trials


Crohn's Disease
Protocol: RHB-104-01

A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease.

Learn More

Crohn's Disease
Protocol: GS-US-419-3895

A Phase 3, double-blind, randomized, placebo-controlled study evaluation the efficacy and safety of Filgotinib in the induction and maintenance of remission subjects with moderately to severe active Crohn’s Disease.

Learn More

Crohn's Disease
Protocol: GS-US-419-3896

An open-label extension study to evaluate the safety of Filgotinib in subjects with Crohn’s Disease.

Learn More

Crohn's Disease
Protocol: 64304500CRD2001

A Phase 2b, randomized, double-blind, placebo controlled, parallel-group, multicenter protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderate to severely active Crohn’s Disease.

Learn More

Crohn's Disease
Protocol: I6T-MC-AMAG

A Phase 2, multicenter, randomized, parallel-arm, placebo-controlled study of LY3074828 in subjects with active Crohn’s Disease (SERENITY).

Learn More

Crohn's Disease
Protocol: RHB-104-01

A Phase III, randomized, double blind, placebo-controlled, multicenter, parallel group study to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with moderately to severely active Crohn’s Disease.

Learn More

Crohn's Disease
Protocol: RHB-104-04

An open label study to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with active Crohn’s Disease despite 26 weeks of participation in the MAP US RHB-104-01 study.

Learn More

Diabetic & Idiopathic Gatroparesis
Protocol: 0099

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis.

Learn More

Nonalcoholic Steatohepatitis (NASH)
Protocol: SHP626-201

A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH).

Learn More

Ulcerative Colitis
Protocol: M14-234

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.

Learn More

Our Research Staff

DHAT Research Institute

7150 N. PRESIDENT GEORGE BUSH HWY, STE. 201 GARLAND, TEXAS 75044

972.265.8201 972.265.8204 RESEARCH@DHAT.COM

Be in the know. Get the latest updates on digestive health.

Copyright 2019 by DHAT - Digestive Health Association of Texas. Terms Of Use |  Privacy Statement
Back To Top